[go: up one dir, main page]

WO2024042231A1 - Adjuvants à base d'adénovirus pour le traitement du cancer - Google Patents

Adjuvants à base d'adénovirus pour le traitement du cancer Download PDF

Info

Publication number
WO2024042231A1
WO2024042231A1 PCT/EP2023/073420 EP2023073420W WO2024042231A1 WO 2024042231 A1 WO2024042231 A1 WO 2024042231A1 EP 2023073420 W EP2023073420 W EP 2023073420W WO 2024042231 A1 WO2024042231 A1 WO 2024042231A1
Authority
WO
WIPO (PCT)
Prior art keywords
adenovirus
cancer
fragment
cells
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2023/073420
Other languages
English (en)
Inventor
Nicolas Gillet
Noémie LEJEUNE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Facultes Universitaires Notre Dame de la Paix
Original Assignee
Facultes Universitaires Notre Dame de la Paix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Facultes Universitaires Notre Dame de la Paix filed Critical Facultes Universitaires Notre Dame de la Paix
Publication of WO2024042231A1 publication Critical patent/WO2024042231A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention concerns the treatment of cancer and more particularly relates to the use of adenovirus as adjuvants.
  • APOBEC3B A large proportion of human tumors are deregulated for the expression of the APOBEC3B gene and express high levels of the APOBEC3B protein.
  • the abnormal expression of this protein has two negative consequences.
  • APOBECB protein fuels the genetic diversity of the tumors, contributing to metastasis and drug resistance.
  • Adenoviruses are a large family of DNA viruses, counting more than 100 genotypes. Adenoviruses are increasingly used as backbone for vaccines and oncolytic viruses.
  • the present invention relates to the use of adenoviruses to antagonize the APOBEC3B protein produced by the tumor cells.
  • the present invention relates to an adenovirus or a fragment thereof for use as an adjuvant for the treatment of cancer in a subject in need thereof.
  • the adenovirus is of a species selected from the group comprising or consisting of B, C, D, E and G.
  • the adenovirus is of a species selected from the group comprising or consisting of B and C.
  • the adenovirus is of a subtype selected from the group comprising or consisting of B3 and C2, preferably B3.
  • the adenovirus is a modified adenovirus comprising at least one nucleic acid mutation compared to a wild type adenovirus.
  • the present invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the adenovirus or a fragment thereof for use according to the invention, and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition further comprises an anticancer agent as an active ingredient.
  • the adenovirus or a fragment thereof is in an amount sufficient to enhance the activity of the anticancer agent. In some embodiments, the adenovirus or a fragment thereof is administered at a dose from about 10 4 to about IO 20 viral particles.
  • the anticancer agent is an oncolytic virus.
  • the adenovirus or a fragment thereof potentiates the replication of said oncolytic virus.
  • the oncolytic virus is selected from the group comprising or consisting of adenovirus, herpes virus, picornavirus, poliovirus, coxsackie virus, poxvirus, vaccina virus, paramyxovirus, measles virus, reovirus, rhabdovirus, vesicular stomatitis virus and senecavirus.
  • the oncolytic virus as adenovirus is distinct from the adenovirus or fragment thereof.
  • the pharmaceutical composition is for use in a method for the treatment of cancer.
  • the cancer is selected from the group comprising or consisting of gastric cancer, gastrointestinal cancer, lung cancer, cervical cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, melanoma, liver cancer, hepatic carcinoma, pancreatic cancer, kidney cancer, ovarian cancer, blood cancer, lymphoma, leukemia, thyroid cancer, squamous cell cancer, brain cancer, glioblastoma, endometrial carcinoma, salivary gland carcinoma, vulvar cancer, and bladder cancer.
  • the present invention further relates to the use of an adenovirus or a fragment thereof for the manufacture of an adjuvant for the treatment of cancer.
  • the present invention further relates to a combination kit comprising (i) an adenovirus or fragment according to the invention, or the pharmaceutical composition according to the invention, and (ii) an anticancer agent, for use for treating cancer in a subject in need thereof.
  • “Fragment”, as used herein, refers to any part of the adenovirus for use according to the present invention.
  • Subject refers to an animal individual, preferably a mammalian individual, more preferably a human individual. In some embodiments, an individual may be a mammalian individual. Mammalians include, but are not limited to, all primates (human and non-human), cattle (including cows), horses, pigs, sheep, goats, dogs, cats, and any other mammal which is awaiting the receipt of, or is receiving medical care or was/is/will be the object of a medical procedure, or is monitored for the development of a disease or condition, preferably cancer.
  • an individual may be a “patient”, /. ⁇ ., a warm-blooded animal, more preferably a human, who/which is awaiting the receipt of, or is receiving medical care or was/is/will be the object of a medical procedure, or is monitored for the development of a disease or condition, preferably cancer.
  • the individual is an adult (e.g., an individual above the age of 18).
  • the individual is a child (e.g., an individual below the age of 18).
  • the individual is a male.
  • the individual is a female.
  • “Pharmaceutically acceptable carrier” refers to a carrier that does not produce any adverse, allergic or other unwanted reactions when administered to an animal individual, preferably a human individual. It includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. For human administration, preparations should meet sterility, pyrogenicity, general safety, quality and purity standards as required by regulatory Offices, such as, e.g., the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in the European Union.
  • FDA Food and Drug Administration
  • EMA European Medicines Agency
  • Treating” or “treatment” refers to both therapeutic treatment and prophylactic or preventative measures; wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder, preferably cancer.
  • Those in need of treatment include those already with the disorder, preferably cancer, as well as those prone to have the disorder or those in whom the disorder is to be prevented.
  • An individual or mammal is successfully “treated” for the disorder if, after receiving a therapeutic amount of an adenovirus vector according to the present invention, the individual shows observable and/or measurable reduction in or absence of one or more of the following: reduction in the number of pathogenic cells (i.e., cancer cells); reduction in the percent of total cells that are pathogenic; and/or relief to some extent, one or more of the symptoms associated with the specific disease or disorder, preferably cancer; reduced morbidity and mortality, and improvement in quality of life issues.
  • pathogenic cells i.e., cancer cells
  • reduction in the percent of total cells that are pathogenic preferably cancer
  • relief to some extent one or more of the symptoms associated with the specific disease or disorder, preferably cancer
  • the above parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician.
  • “Therapeutically effective amount” refers to the level or amount of an agent that is aimed at, without causing significant negative or adverse side effects to the target, (1) delaying or preventing the onset of the disease or condition, preferably cancer; (2) slowing down or stopping the progression, aggravation, or deterioration of one or more symptoms of the disease or condition, preferably cancer; (3) bringing about ameliorations of the symptoms of the disease or condition, preferably cancer; (4) reducing the severity or incidence of the disease or condition, preferably cancer; or (5) curing the disease or condition, preferably cancer.
  • a therapeutically effective amount may be administered prior to the onset of the disease or condition, for a prophylactic or preventive action. Alternatively, or additionally, the therapeutically effective amount may be administered after initiation of the disease or condition, preferably cancer, for a therapeutic action.
  • the present invention relates to an adenovirus or a fragment thereof for use as an adjuvant for the treatment of cancer in a subject in need thereof.
  • the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of A, B, C,
  • the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of B, C, D,
  • the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of B, C, D, E and G.
  • the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of B, C, D and E, or from the group comprising or consisting of B, C, D and G, or from the group comprising or consisting of B, C, E and G, or from the group comprising or consisting of
  • the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of B, C, D,
  • the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of B, C, and D, or from the group comprising or consisting of B, C and E, or from the group comprising or consisting of B, D and E, or from the group comprising or consisting of C, D and E.
  • the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of B, C, D. In certain embodiments, the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of B and C, or from the group comprising or consisting of B and D, or from the group comprising or consisting of C and D.
  • the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of B and
  • the adenovirus or fragment thereof for use according to the invention is of species B. In a more preferred embodiment, the adenovirus or fragment thereof for use according to the invention is of species C. In another embodiment, the adenovirus or fragment thereof for use according to the invention is of species D. In another embodiment, the adenovirus or fragment thereof for use according to the invention is of species E. In another embodiment, the adenovirus or fragment thereof for use according to the invention is of species G.
  • the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of A, C and
  • the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of A and C. In one embodiment, the adenovirus or fragment thereof for use according to the invention is of species A. In one embodiment, the adenovirus or fragment thereof for use according to the invention is of species C. In one embodiment, the adenovirus or fragment thereof for use according to the invention is of species F.
  • the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of B, A and C. In one embodiment, the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of B and A. In one embodiment, the adenovirus or fragment thereof for use according to the invention is of a species selected from the group comprising or consisting of B and C.
  • the adenovirus or fragment thereof for use according to the invention is of a subtype selected from the group comprising or consisting of A12, A18, A31, B3, B7, Bl l, B14, B16, B21, B34, B35, B50, B55, Cl, C2, C5, C6, C57, D8, D9, D10, D13, D15, D17, D19, D20, D22, D23, D24, D25, D26, D27, D28, D29, D30, D32, D33, D36, D37, D38, D39, D42, D43, D44, D45, D46, D47, D48, D49, D51, D53, D54, D56, D58, D59, D60, D62, D63, D64, D65, D67, D69, D70, D71, D72, D73, D74, D75, E4, F40, F41 and G52.
  • the adenovirus or fragment thereof for use according to the invention is of a subtype selected from the group comprising or consisting of B3, B7, Bl l, B14, B16, B21, B34, B35, B50, B55, Cl, C2, C5, C6, C57, D8, D9, D10, D13, D15, D17, D19, D20, D22, D23, D24, D25, D26, D27, D28, D29, D30, D32, D33, D36, D37, D38, D39, D42, D43, D44, D45, D46, D47, D48, D49, D51, D53, D54, D56, D58, D59, D60, D62, D63, D64, D65, D67, D69, D70, D71, D72, D73, D74, D75, E4, F40, F41 and G52.
  • the adenovirus or fragment thereof for use according to the invention is of a subtype selected from the group comprising or consisting of A12, A18, A31, B3, B7, Bl l, B14, B16, B21, B34, B35, B50, B55, Cl, C2, C5, C6 and C57.
  • the adenovirus or fragment thereof for use according to the invention is of a subtype selected from the group comprising or consisting of A12, B3 and C2.
  • the adenovirus or fragment thereof for use according to the invention is of subtype B3.
  • the adenovirus or fragment thereof for use according to the invention is of subtype A12.
  • the adenovirus or fragment thereof for use according to the invention is of subtype C2.
  • the adenovirus or fragment thereof for use according to the invention is of a subtype selected from the group comprising or consisting of B3, B7, Bl l, B14, B16, B21, B34, B35, B50, B55, Cl, C2, C5, C6 and C57.
  • the adenovirus or fragment thereof for use according to the invention is of a subtype selected from the group comprising or consisting of B3 and C2.
  • the adenovirus or fragment thereof for use according to the invention is of subtype B3.
  • the adenovirus or fragment thereof for use according to the invention is of subtype C2.
  • adenovirus or fragment thereof from the B3 and C12 decrease the quantity of ABOBEC2B with an enhanced efficacity than the other species of adenovirus.
  • this effect is particularly significative with the B3 subtype.
  • the adenovirus or fragment thereof for use according to the invention is of a subtype selected from the group comprising or consisting of B3, B7, Bl l, B14, B16, B21, B34, B35, B50, B55, D8, D9, D10, D13, D15, D17, D19, D20, D22, D23, D24, D25, D26, D27, D28, D29, D30, D32, D33, D36, D37, D38, D39, D42, D43, D44, D45, D46, D47, D48, D49, D51, D53, D54, D56, D58, D59, D60, D62, D63, D64, D65, D67, D69, D70, D71, D72, D73, D74, D75, E4 and G52.
  • the adenovirus or fragment thereof for use according to the invention is of a subtype selected from the group comprising or consisting of Cl, C2, C5, C6, C57, D8, D9, D10, D13, D15, D17, D19, D20, D22, D23, D24, D25, D26, D27, D28, D29, D30, D32, D33, D36, D37, D38, D39, D42, D43, D44, D45, D46, D47, D48, D49, D51, D53, D54, D56, D58, D59, D60, D62, D63, D64, D65, D67, D69, D70, D71, D72, D73, D74, D75, E4, and G52.
  • adenovirus or fragment thereof for use according to the invention is not from the A species. In some embodiment adenovirus or fragment thereof for use according to the invention is not of a subtype selected from the group comprising or consisting of A12, Al 8, A31. In some embodiment adenovirus or fragment thereof for use according to the invention is not the A12 subtype.
  • the adenovirus or fragment thereof for use according to the invention is safe for mammalian administration, preferably human administration. In some embodiments, the adenovirus or fragment thereof for use according to the invention does not produce an adverse, allergic or other untoward reaction in the subject.
  • the adenovirus or fragment thereof for use according to the invention has an increased tropism for cancer cells.
  • “increased tropism” means that the infection rate of the adenovirus or fragment thereof for cancer cells is 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 100-fold, 500-fold, 1,000-fold or more than healthy cells.
  • the adenovirus or fragment thereof for use according to the invention preferentially infects cancer cells.
  • the adenovirus or fragment thereof for use according to the invention exclusively infects cancer cells.
  • the adenovirus or fragment thereof for use according to the invention inhibits or antagonizes the apolipoprotein B mRNA editing enzyme catalytic polypeptide-like (APOBEC) family of proteins.
  • APOBEC catalytic polypeptide-like
  • the adenovirus or fragment thereof for use according to the invention inhibits or antagonizes an APOBEC 3 protein selected from the group comprising or consisting of APOBEC3 A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G and APOBEC3H.
  • the adenovirus or fragment thereof for use according to the invention inhibits or antagonizes APOBEC3B (or “A3B”).
  • the adenovirus or fragment thereof for use according to the invention that inhibits or antagonizes APOBEC3B is of a species selected from the group comprising or consisting from the B and C.
  • the adenovirus or fragment thereof for use according to the invention that inhibits or antagonizes APOBEC3B is of a subtype selected from the group comprising or consisting from the B3 and C12 subtypes.
  • the adenovirus or fragment thereof for use according to the invention that inhibits or antagonizes APOBEC3B is not from the A species.
  • the adenovirus or fragment thereof for use according to the invention reduces the quantity of A3B in a cell.
  • “reduces the quantity of A3B” means that the number of A3B proteins is decreased 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 100-fold, 500-fold, 1,000-fold or more compared to the number of A3B proteins in an uninfected cell.
  • the adenovirus or fragment thereof for use according to the invention reduces the quantity of A3B in a cell to the levels normally found in a healthy cell, wherein the infected cell expresses higher levels of A3B compared to a healthy cell (e.g., a cancer cell). In certain embodiments, the adenovirus or fragment thereof for use according to the invention reduces the quantity of A3B in a cell to levels below those normally found in a healthy cell.
  • Methods for measuring the quantity of A3B in cells are well-known from the skilled person in the art. Measurements may be performed at the RNA level or the protein level.
  • the adenovirus or fragment thereof for use according to the invention inhibits the enzymatic activity of A3B. In a preferred embodiment, the adenovirus or fragment thereof for use according to the invention inhibits the cytidine deaminase activity of A3B.
  • inhibits the activity of A3B means that the activity of A3B is decreased 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8- fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 100- fold, 500-fold, 1,000-fold or more compared to A3B activity in an uninfected cell.
  • the adenovirus or fragment thereof for use according to the invention has an increased tropism for cells overexpressing A3B and/or cells having an increased A3B activity.
  • the adenovirus or fragment thereof for use according to the invention acts as a lytic virus and induces cell death in the infected cell.
  • the adenovirus or fragment thereof for use according to the invention acts as an oncolytic virus and induces cell death in the infected cancer cell.
  • the adenovirus or fragment thereof for use according to the invention induces cell death in a population of cancer cells.
  • the fragments of said adenovirus from the present invention retain at least the biological function of the adenovirus.
  • adenovirus may refer interchangeably to both naturally occurring (or “wild type”) adenoviruses, and adenoviruses that have been genetically modified/engineered, /. ⁇ ., mutant adenoviruses.
  • the adenovirus or fragment thereof for use according to the invention is a wild type adenovirus, or a modified adenovirus comprising at least one nucleic acid mutation compared to a wild type adenovirus.
  • the adenovirus or fragment thereof for use according to the invention is a wild type adenovirus.
  • the adenovirus or fragment thereof for use according to the invention is a modified adenovirus or fragment thereof comprising at least one nucleic acid mutation compared to a wild type adenovirus.
  • at least one means 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, 20 or more.
  • nucleic acid mutation comprises substitutions, deletions, insertions, inversions, point mutations, frameshift mutations and combination thereof.
  • the mutation increases or decreases the ability of the adenovirus or fragment thereof for use according to the invention to infect cells. In one embodiment, the mutation increases the ability of the adenovirus or fragment thereof for use according to the invention to infect cells. In another embodiment, the mutation decreases the ability of the adenovirus or fragment thereof for use according to the invention to infect cells.
  • the mutation increases or decreases the ability of the adenovirus or fragment thereof for use according to the invention to replicate. In one embodiment, the mutation increases the ability of the adenovirus or fragment thereof for use according to the invention to replicate. In another embodiment, the mutation decreases the ability of the adenovirus or fragment thereof for use according to the invention to replicate.
  • the mutation increases the tropism for cancer cells of the adenovirus or fragment thereof for use according to the invention.
  • the adenovirus or fragment thereof for use according to the invention comprises at least one heterologous sequence or peptide.
  • heterologous sequence or peptide is meant a sequence or peptide which is not endogenous or native to the adenovirus.
  • the nucleic acid of the heterologous peptide is inserted into the nucleic acid of the adenovirus.
  • the adenovirus or fragment thereof is not a helperdependent adenovirus.
  • the present invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the adenovirus or a fragment thereof for use according to the invention and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier is selected in a group comprising or consisting of a solvent, a diluent, a carrier, an excipient, a dispersion medium, a coating, an antibacterial agent, an antifungal agent, an isotonic agent, an absorption delaying agent and any combinations thereof.
  • the carrier, diluent, solvent or excipient must be “acceptable” in the sense of being compatible with the polypeptide, or derivative thereof, and not be deleterious upon being administered to a subject.
  • the vehicle does not produce an adverse, allergic or other untoward reaction when administered to a subject, preferably a human subject.
  • the pharmaceutical compositions should meet sterility, pyrogenicity, general safety and purity standards as required by regulatory offices, such as, for example, the Food and Drugs Administration (FDA) Office or the European Medicines Agency (EMA).
  • FDA Food and Drugs Administration
  • EMA European Medicines Agency
  • the carrier may be water or saline (e.g., physiological saline), which will be sterile and pyrogen free.
  • Suitable excipients include mannitol, dextrose, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like.
  • the pharmaceutical composition for use according to the invention further comprises an anticancer agent as an active ingredient.
  • the anticancer agent is an oncolytic virus or a commercially available anticancer medicament.
  • the adenovirus or a fragment thereof for use according to the invention is in an amount sufficient to enhance the activity of the anticancer agent.
  • the adenovirus or a fragment thereof increases the oncolytic effects and/or oncostatic effects, preferably oncolytic effects, of the anticancer agent are increased 1.2- fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4- fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 100-fold, 500-fold, 1,000-fold or more.
  • the adenovirus or a fragment thereof for use according to the invention improves the anticancer effects of the anticancer agent.
  • the cancer cells are eliminated, and/or the tumor regresses, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 100 times, 500 times, 1,000 times faster or more.
  • adenovirus or a fragment thereof for use according to the invention acts as an adjuvant for the anticancer agent.
  • the anticancer agent is an oncolytic virus.
  • the oncolytic virus is selected from the group comprising or consisting of adenovirus, herpes virus, picornavirus, poliovirus, coxsackie virus, poxvirus, vaccina virus, paramyxovirus, measles virus, reovirus, rhabdovirus, vesicular stomatitis virus and senecavirus.
  • the oncolytic virus is another adenovirus, wherein the other adenovirus is distinct from the adenovirus or fragment thereof for use according to the invention.
  • the oncolytic virus is a herpes virus.
  • the oncolytic virus is a picornavirus.
  • the oncolytic virus is a poliovirus.
  • the oncolytic virus is a coxsackie virus.
  • the oncolytic virus is a poxvirus.
  • the oncolytic virus is a vaccina virus.
  • the oncolytic virus is a paramyxovirus.
  • the oncolytic virus is a measles virus. In some embodiments, the oncolytic virus is a reovirus. In some embodiments, the oncolytic virus is a rhabdovirus. In some embodiments, the oncolytic virus is a vesicular stomatitis virus. In some embodiments, the oncolytic virus is a senecavirus.
  • the adenovirus or a fragment thereof for use according to the invention potentiates the replication of the oncolytic virus.
  • “potentiates the replication” means that the oncolytic virus replicates 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6- fold, 7-fold, 8-fold, 9-fold, 10-fold faster, or more.
  • the adenovirus or a fragment thereof for use according to the invention promotes the late phase replication of the oncolytic virus.
  • adenovirus or a fragment thereof for use according to the invention acts as an adjuvant for the oncolytic virus.
  • the anticancer agent is a commercially available anticancer medicament, e.g., a pharmacological agent, an antibody or fragment thereof, a nucleic acid for gene therapy or vector comprising thereof, and the like.
  • anticancer medicament are known from the state of the art include, e.g., acalabrutinib, alectinib, alemtuzumab, anastrozole, avapritinib, avelumab, belinostat, bevacizumab, bleomycin, blinatumomab, bosutinib, brigatinib, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin copanlisib, cytarabine, daunorubicin, decitabine, dexamethasone, docetaxel, doxorubicin, encorafenib, erdafitinib, etoposide, everolimus, exemestane, fludarabine, 5-fluorouracil, gemcitabine, ifosfamide, imatinib Mesylate, leuprolide,
  • the adenovirus or a fragment thereof and/or the pharmaceutical composition is for use in a method for the treatment of cancer.
  • cancer is intended to refer to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
  • cancer and “cancerous” are intended to refer to, or to describe, the physiological condition in mammals that is typically characterized by unregulated cell growth or proliferation.
  • Non-limitative examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include, without limitation, breast cancer, prostate cancer, colon cancer, squamous cell cancer, lung cancer (including small-cell lung cancer and non-small cell lung cancer), gastrointestinal cancer, gastric cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, vulvar cancer, thyroid cancer, lymphoma, hepatic carcinoma and various types of head and neck cancer.
  • the cancer is selected from the group comprising or consisting of gastric cancer, gastrointestinal cancer, lung cancer, cervical cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, melanoma, liver cancer, hepatic carcinoma, pancreatic cancer, kidney cancer, ovarian cancer, blood cancer, lymphoma, leukemia, thyroid cancer, squamous cell cancer, brain cancer, glioblastoma, endometrial carcinoma, salivary gland carcinoma, vulvar cancer, and bladder cancer.
  • the cancer is selected from the group comprising or consisting of gastric cancer, lung cancer, cervical cancer, colorectal cancer, breast cancer, prostate cancer, melanoma, liver cancer, pancreatic cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, thyroid cancer and bladder cancer.
  • the cancer cells have an increased expression of A3B and/or an increased A3B activity compared to healthy cells.
  • the cancer cells have an increased expression of A3B compared to healthy cells.
  • “increased expression of A3B” means that the expression of A3B in cancer cells is increased 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6- fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9- fold, 10-fold, 100-fold, 500-fold, 1,000-fold or more compared to healthy cells.
  • the cancer cells have an increased A3B activity compared to healthy cells.
  • “increased A3B activity” means that the enzymatic activity of A3B in cancer cells is increased 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10- fold, 100-fold, 500-fold, 1,000-fold or more compared to healthy cells.
  • the adenovirus or fragment thereof for use according to the invention, or the pharmaceutical composition for use according to the invention is to be administered to an individual in need thereof by any suitable route, /. ⁇ ., by a dermal administration, by an oral administration, a topical administration or a parenteral administration, e.g., by injection, including a subcutaneous administration, a venous administration, an arterial administration, in intramuscular administration, an intraocular administration, an intracardiac administration and an intra-auricular administration.
  • the adenovirus or fragment thereof for use according to the invention, or the pharmaceutical composition for use according to the invention is to be administered to an individual in need thereof by intravenous, intra-arterial, intramuscular, intradermal, subcutaneous, intraocular or intracardiac injection.
  • the adenovirus or fragment thereof for use according to the invention, or the pharmaceutical composition for use according to the invention is to be administered to an individual in need thereof by a dermal administration.
  • the adenovirus or fragment thereof for use according to the invention, or the pharmaceutical composition for use according to the invention is to be administered to an individual in need thereof by an oral administration.
  • the adenovirus or fragment thereof for use according to the invention is administered prior, concomitantly or after the anticancer agent. In some embodiments, the adenovirus or fragment thereof for use according to the invention is administered prior to the anticancer agent, preferably between about 1 month and about 1 minute prior to the anticancer agent. In some embodiments, the adenovirus or fragment thereof for use according to the invention is administered concomitantly with the anticancer agent. In some embodiments, the adenovirus or fragment thereof for use according to the invention is administered after the anticancer agent, preferably between about 1 minute and about 1 month after the anticancer agent.
  • the adenovirus or fragment thereof for use according to the invention, or the pharmaceutical composition for use according to the invention is to be administered in one or multiple administrations. In some embodiments, the adenovirus or fragment thereof for use or the pharmaceutical composition for use according to the invention is to be administered in 1, 2, 3, 4, 5, 6, 7, 8, 9 administrations, ore more. In certain embodiments, the adenovirus or fragment thereof for use or the pharmaceutical composition for use according to the invention is to be administered until the cancer is treated or cured.
  • the adenovirus or fragment thereof for use or the pharmaceutical composition for use according to the invention is to be administered in a therapeutically effective amount.
  • the therapeutically effective amount of the adenovirus or fragment thereof for use or the pharmaceutical composition for use according to the invention, to be administered may be determined by a physician or an authorized person skilled in the art and can be suitably adapted within the time course of the treatment.
  • the therapeutically effective amount to be administered may depend upon a variety of parameters, including the material selected for administration, whether the administration is in single or multiple doses, and the individual’s parameters including age, physical conditions, size, weight, gender, and the severity of the age-related disease to be treated.
  • the adenovirus or fragment thereof for use or the pharmaceutical composition for use according to the invention is administered at a dose from about 10 3 to about IO 20 pfu.
  • pfu plaque forming unit
  • plaque forming unit corresponds to the infectivity of a virus solution, and is determined by infection of a suitable cell culture, and measurement, generally after 15 days, the number of areas of infected cells. The techniques for determining the pfu titer of a viral solution are well documented in the art.
  • the adenovirus or fragment thereof for use or the pharmaceutical composition for use according to the invention is administered at a dose from about 10 4 to about IO 20 pfu, from about 10 5 to about IO 20 pfu, from about 10 6 to about IO 20 pfu, from about 10 7 to about IO 20 pfu, from about 10 8 to about IO 20 pfu, from about 10 9 to about IO 20 pfu, from about 10 10 to about IO 20 pfu, from about 10 11 to about IO 20 pfu, from about 10 12 to about IO 20 pfu, from about 10 13 to about IO 20 pfu, from about 10 14 to about IO 20 pfu, from about 10 15 to about IO 20 pfu, from about 10 16 to about IO 20 pfu, from about 10 17 to about IO 20 pfu, from about 10 18 to about IO 20 pfu, from about 10 19 to about IO 20
  • the adenovirus or fragment thereof for use or the pharmaceutical composition for use according to the invention is administered at a dose from about 10 3 to about 10 19 pfu, from about 10 3 to about 10 18 pfu, from about 10 3 to about 10 17 pfu, from about 10 3 to about 10 16 pfu, from about 10 3 to about 10 15 pfu, from about 10 3 to about 10 14 pfu, from about 10 3 to about 10 13 pfu, from about 10 3 to about 10 12 pfu, from about 10 3 to about 10 11 pfu, from about 10 3 to about 10 10 pfu, from about 10 3 to about 10 9 pfu, from about 10 3 to about 10 8 pfu, from about 10 3 to about 10 7 pfu, from about 10 3 to about 10 6 pfu, from about 10 3 to about 10 5 pfu, from about 10 3 to about 10 4 pfu.
  • the adenovirus or fragment thereof for use or the pharmaceutical composition for use according to the invention is administered at a dose from about 10 4 to about IO 20 viral particles, from about 10 5 to about IO 20 viral particles, from about 10 6 to about IO 20 viral particles, from about 10 7 to about IO 20 viral particles, from about 10 8 to about IO 20 viral particles, from about 10 9 to about IO 20 viral particles, from about 10 10 to about IO 20 viral particles, from about 10 11 to about IO 20 viral particles, from about 10 12 to about IO 20 viral particles, from about 10 13 to about IO 20 viral particles, from about 10 14 to about IO 20 viral particles, from about 10 15 to about IO 20 viral particles, from about 10 16 to about IO 20 viral particles, from about 10 17 to about IO 20 viral particles, from about 10 18 to about IO 20 viral particles, from about 10 19 to about IO 20 viral particles.
  • the adenovirus or fragment thereof for use or the pharmaceutical composition for use according to the invention is administered at a dose from about 10 3 to about 10 19 viral particles, from about 10 3 to about 10 18 viral particles, from about 10 3 to about 10 17 viral particles, from about 10 3 to about 10 16 viral particles, from about 10 3 to about 10 15 viral particles, from about 10 3 to about 10 14 viral particles, from about 10 3 to about 10 13 viral particles, from about 10 3 to about 10 12 viral particles, from about 10 3 to about 10 11 viral particles, from about 10 3 to about 10 10 viral particles, from about 10 3 to about 10 9 viral particles, from about 10 3 to about 10 8 viral particles, from about 10 3 to about 10 7 viral particles, from about 10 3 to about 10 6 viral particles, from about 10 3 to about 10 5 viral particles, from about 10 3 to about 10 4 viral particles.
  • the adenovirus or fragment thereof for use or the pharmaceutical composition for use according to the invention is administered at a dose from about 0.001 mg to about 10,000 mg.
  • the adenovirus or fragment thereof for use or the pharmaceutical composition for use according to the invention is administered at a dose from about 0.01 mg to about 10,000 mg, from about 0.1 mg to about 10,000 mg, from about 1 mg to about 10,000 mg, from about 10 mg to about 10,000 mg, from about 100 mg to about 10,000 mg, from about 1,000 mg to about 10,000 mg.
  • the adenovirus or fragment thereof for use or the pharmaceutical composition for use according to the invention is administered at a dose from about 0.001 mg to about 1,000 mg, from about 0.001 mg to about 100 mg, from about 0.001 mg to about 10 mg, from about 0.001 mg to about 1 mg, from about 0.001 mg to about 0.1 mg, from about 0.001 mg to about 0.01 mg.
  • the present invention further relates to the use of an adenovirus or a fragment thereof, or a pharmaceutical composition comprising the same, for the manufacture of an adjuvant for the treatment of cancer.
  • the adjuvant comprises a therapeutically effective amount of the adenovirus or a fragment thereof, or of the pharmaceutical composition, as described hereinabove.
  • the adjuvant is a medicament for the treatment of cancer.
  • the present invention further relates to a combination kit comprising (i) the adenovirus or fragment according to the invention, the pharmaceutical composition according to the invention, or the adjuvant according to the invention, and (ii) means for administering the first part, for use for treating cancer in a subject in need thereof.
  • the combination kit further comprises an anticancer agent. In some embodiments, the combination kit further comprises means for administering the anticancer agent.
  • the present invention further relates to a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of an adenovirus or fragment thereof as an adjuvant, or a pharmaceutical composition comprising the same.
  • the method further comprises the administration of an anticancer agent as an active ingredient.
  • the anticancer adjuvant according to the invention and the anticancer agent are comprised in the same composition.
  • the anticancer adjuvant according to the invention and the anticancer agent are comprised in different compositions.
  • the adenovirus or fragment thereof is of a subtype selected from the group comprising or consisting of A12, Al 8, A31, B3, B7, Bl 1, B14, B16, B21, B34, B35, B50, B55, Cl, C2, C5, C6 and C57.
  • the adenovirus or fragment thereof is of a subtype selected from the group comprising or consisting of A12, B3 and C2.
  • the adenovirus or fragment thereof is of a subtype selected from the group comprising or consisting of B3 and C2.
  • the adenovirus or fragment thereof is of subtype B3.
  • the adenovirus or fragment thereof is a modified adenovirus.
  • the adenovirus or fragment thereof does not encode for a cytokine. In some embodiments, the adenovirus or fragment thereof does not encode for degradation factor for the extracellular matrix. In some embodiments, the adenovirus or fragment thereof does not encode for any adjuvant. In some embodiments, the adenovirus or fragment thereof does not encode for an active agent. In some embodiments, the adenovirus or fragment thereof does not encode for an immunomodulatory factor. In some embodiments, the adenovirus or fragment thereof does not encode for a therapeutic molecule. In a certain embodiment, the adenovirus or fragment thereof does not encode for a protein. In a preferred embodiment, the adenovirus or fragment thereof is an empty vector.
  • the adenovirus or fragment thereof, or the pharmaceutical composition comprising the same is to be administered by any suitable route, /. ⁇ ., by a dermal administration, by an oral administration, a topical administration or a parenteral administration, e.g., by injection, including a subcutaneous administration, a venous administration, an arterial administration, in intramuscular administration, an intraocular administration, an intracardiac administration and an intra-auricular administration.
  • the adenovirus or fragment thereof, or the pharmaceutical composition comprising the same is to be administered at a dose from about 10 3 to about IO 20 pfu. In some embodiments, the adenovirus or fragment thereof, or the pharmaceutical composition comprising the same, is to be administered at a dose from about 10 3 to about IO 20 viral particles. In some embodiments, the adenovirus or fragment thereof, or the pharmaceutical composition comprising the same, is to be administered at a dose from about 0.001 mg to about 10,000 mg.
  • the present invention further relates to a method for inhibiting the protein APOBEC3B (A3B) in a subject in need thereof, comprising administering to the subject an effective amount of an adenovirus or fragment thereof, or a composition comprising the same.
  • A3B protein APOBEC3B
  • inhibiting the protein A3B means that the activity of A3B is decreased 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2- fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 100-fold, 1,000-fold or more.
  • the method is a method for inhibiting the cytidine deaminase activity of A3B.
  • the decrease of activity is caused by a decrease of the quantity of A3B protein.
  • the present invention further relates to an in vitro method for inhibiting the protein APOBEC3B (A3B) in a population of cells, comprising administering to the population of cells an effective amount of an adenovirus or fragment thereof or composition comprising the same.
  • A3B protein APOBEC3B
  • Figure 1A-1C is a combination of photographs and histograms showing the establishment of bronchial epithelial cells over-expressing A3B.
  • Immortalized human bronchial epithelial cells HBEC3-KT were transduced to stably express the GFP, the APOBEC3B protein (A3B) or a catalytically inactive version of the APOBEC3B protein (A3B-DD for Deaminase Dead).
  • A3B mRNA levels were quantified by RTqPCR and expressed relative to the amount produced by wild type HBEC3-KT cells (WT).
  • IB A3B protein levels were assessed by western blot, quantified by densitometry and expressed relative to the amount produced by WT cells.
  • Fig. 1C Total proteins were extracted in a non-denaturing buffer and mixed with the substrate of the deamination assay. Deaminase activity, if present in the cell lysate, will allow the conversion of substrates into shorter products. Substrates and products were quantified by densitometry. Deamination activities of the cell lysates were expressed as the percentage of substrate converted into product. P-values were calculated by t-tests.
  • Figure 2A-2C is a set of histograms showing that A3B restricts adenoviruses by a deaminase-dependent mechanism.
  • Fig. 2A Intracellular viral DNA levels were quantified by qPCR and expressed relative to the levels measured in WT cells.
  • Viral DNA levels in the supernatant were quantified by qPCR and expressed relative to the levels measured in the supernatant of WT cells.
  • Fig. 2C The percentage of infected cells were quantified by flow cytometry and expressed relative to the percentages measured in WT cells.
  • Figure 3A-3C is a set of histograms showing that A3B reduces viral load, progression to late phase and production of infectious viral particles.
  • Fig. 3A The levels of different viral mRNAs were quantified by RTqPCR and expressed relative to their amounts measured in WT cells. An immediate early transcript (E1A), an early transcript (E4orf6) and a late transcript (Penton) were quantified.
  • E1A immediate early transcript
  • E4orf6 an early transcript
  • Penton late transcript
  • Figure 4A-4E is a combination of photograph, schemes and histograms showing that A3B hypermutates the adenovirus genomes.
  • HBEC-WT, -GFP, -A3B and -A3B-DD were infected with HAdV-A12, -B3 or -C2 and the intracellular DNAs were extracted 48 hours post infection. 3DPCR reactions were conducted on the E1B, L3 and E4 genes.
  • Fig. 4A Agarose gels illustrating 3DPCRs specific for the E4 gene of the A12 strain. The dotted white line indicates the threshold between mutated and unmutated 3DPCR products. Low denaturation temperature amplicons were recovered in HBEC-A3B cells only.
  • Fig. 4A Agarose gels illustrating 3DPCRs specific for the E4 gene of the A12 strain. The dotted white line indicates the threshold between mutated and unmutated 3DPCR products. Low denaturation temperature amplicons were recovered in HBEC-
  • FIG. 4B Graphical representation of the 3DPCR results obtained for the 3 viral genes (E1B, L3 and E4), for the 3 viral strains (A12, B3 and C2) and for the 4 cell lines (WT, GFP, A3B and A3B-DD). The lowest denaturation temperatures allowing the production of the expected amplicons were represented on the gradients by colored circles.
  • FIG. 4C 3DPCR products generated from HAdV-A12-infected WT and A3B- expressing cells were cloned and sequenced. Hypermutated sequences detected in A3B- expressing cells (A3B) were aligned against the reference viral genome (Ref) and against sequences isolated from WT infected cells (WT).
  • FIG. 5A-5C is a combination of photographs and histograms showing the establishment of A3B knockout lung cancer cells.
  • A549 lung cancer cells were transduced to stably express APOBEC3B-targeting shRNAs (shA3B) or a nontargeting control shRNA (scramble).
  • shA3B APOBEC3B-targeting shRNAs
  • scramble APOBEC3B-targeting shRNAs
  • Fig. 5A A3B mRNA levels were quantified by RTqPCR and expressed relative to the amount produced by wild type A549 cells (WT).
  • Fig. 5B A3B protein levels were assessed by western blot, quantified by densitometry and expressed relative to the amount produced by WT cells.
  • Fig. 5C Deamination activities of the cell lysates were expressed as the percentage of substrate converted into product and compared to the deamination activity of the WT cells. P-values were calculated by t-tests.
  • Figure 6A-6C is a combination of photograph, schemes and histograms showing that A3B knockout promotes replication of strain A12 and reduces the presence of hyper- mutated viral genomes.
  • Fig. 6A Intracellular viral DNA levels were quantified by qPCR and expressed relative to the levels measured in WT cells.
  • Viral DNA levels in the supernatant were quantified by qPCR and expressed relative to the levels measured in the supernatant of WT cells.
  • Fig. 6C The percentage of infected cells were quantified by flow cytometry and expressed relative to the percentages measured in WT cells. P-values were calculated by t-tests.
  • Figure 7A-7B is a combination of photograph, schemes showing that hypermutated viruses are not detected in A3B-KO-infected cells. 3DPCR reactions were conducted on the E1B, L3 and E4 genes.
  • Fig. 7A Agarose gels illustrating 3DPCRs specific for the L3 gene of the A12 strain. The dotted white line indicates the threshold between mutated and unmutated 3DPCR products.
  • Fig. 7B Graphical representation of the 3DPCR results obtained for the 3 viral genes (E1B, L3 and E4), for the 3 viral strains (A12, B3 and C2) and for the 3 cell lines (WT, scramble and shA3B). The lowest denaturation temperatures allowing the production of the expected amplicons were represented on the gradients.
  • Figure 8A-8E is a combination of photographs and histograms showing that adenoviruses antagonize A3B with varying efficiencies between strains.
  • Fig. 8A A3B protein levels were assessed by western blot at 1- and 2-days post infection, quantified by densitometry and expressed relative to the amount produced by mock-infected cells.
  • Fig. 8B A3B mRNA levels were quantified by RTqPCR at 1- and 2-days post infection and expressed relative to GAPDH mRNA.
  • FIG. 8C Deamination activities of the cell lysates were expressed as the percentage of substrate converted into product and compared to the deamination activities of the mock-infected cells at 1- and 2-days post infection.
  • FIG. 8D The viral replication centers as identified by EdU labelling and the A3B protein were imaged by fluorescence microscopy.
  • Fig. 8E EdU and A3B fluorescence intensities were reported in cross-sections for colocalization analysis. P-values were calculated by t- tests.
  • Figure 9 is a graph showing that adenoviruses of a given species share a similar A3 footprint. The NTC codon observed/expected ratios were calculated in 70 different adenoviruses spanning the 7 species.
  • HBEC3-KT cells are normal human bronchial epithelial cells immortalized with the human TERT and mouse Cdk4 genes.
  • HBEC3-KT cells were obtained from UT Southwestern, Dallas, Texas, USA.
  • HBEC3-KT were cultured in keratinocyte-SFM medium supplemented with bovine pituitary extract (50 pg/mL) and human recombinant epidermal growth factor (5 ng/mL) (Gibco) on gelatin-coated flasks.
  • HBEC3-KT constitutively expressing GFP (HBEC-GFP), A3B (HBEC-A3B) or A3B Deaminase Dead (HBEC-A3B-DD) were established by transduction with lentiviral vectors encoding for a GFP, A3B or A3B-DD protein (pLenti4-A3B and pLenti4-A3B-E68Q-E255Q encoding respectively the catalytically active and inactive A3B).
  • the human lung carcinoma cell line A549 (American Type Culture Collection) and PKR-deficient A549 cell line were cultured in Dulbecco’s Modified Eagle’s medium (Gibco) supplemented with 10% fetal calf serum (Gibco) and 10 mM of L-glutamine.
  • PKR-deficient A549 cells were obtained from UTMB, Galveston, Texas, USA.
  • A549 cells knock-down for A3B (A549 A3B shRNAs) were established by transduction with lentiviral vectors encoding A3B-targeting shRNAs (pSicoR-MS2 plasmids).
  • A549 cells were also transduced with a lentiviral vector encoding non-targeting shRNA (A549 NTC shRNA) and used as control.
  • A549 NTC shRNA lentiviral vector encoding non-targeting shRNA
  • puromycin markers originally present in the pSicoR-M2 and pLenti4-A3B plasmids have been replaced by a blasticidin resistance gene prior A549 or HBEC3-KT transduction.
  • Blasticidin was used to select for a polyclonal population of effectively transduced cells. All cell lines were incubated at 37°C and 5% CO2. Virus preparation procedure
  • Adenovirus A12 (HAdV-12, ATCC VR863) was purchased at the American Type Culture Collection.
  • Adenoviruses B3 and -C2 were obtained from KULeuven, Leuven, Belgium and strain identity was verified by genotyping as published in (Lejeune et al., 2021) and using primers described in (Wang et al., 2013).
  • HAdV-B3 and -C2 viral stocks were produced in A549 cells and HAdV-A12 viral stock in PKR-deficient A549 cells.
  • A549 cells and PKR-deficient A549 cells were cultured in OPTLMEM®! Reduced-Serum Medium without phenol red (ThermoFisher Scientific). When 80% of the cells showed cytopathic effects, cells were scraped, collected with the culture medium and centrifuged at 3,500g for 15 minutes. The supernatant was collected and set aside. The cell pellet was resuspended in 2 mL of culture medium, submitted to 3 freeze/thaw cycles and centrifuged at 3,500g for 15 minutes.
  • the supernatant was collected, pooled with the previous supernatant and treated with the endonuclease Benzonase® (1 U/mL) (Sigma-Aldrich) at 37°C for 30 minutes to degrade the unpackaged nucleic acids.
  • Supernatant was then filtered on a 0.22 pm Steriflip® Filters (Merck Millipore) to remove residual cell debris.
  • Eluate was collected and further filtered through Amicon® Ultra- 15 Centrifugal Filter Unit 100 KDa (Merck Millipore). Virions were retained on the filter, resuspended in PBS and stored at -80°C.
  • HBEC3-KT cells were infected with the HAdV-A12, -B3 or -C2 strain at a multiplicity of infection (MOI) of 0.03 or 3 in keratinocyte-SFM medium supplemented with bovine pituitary extract (50 pg/mL) and human recombinant epidermal growth factor (5 ng/mL) (Gibco) on gelatin-coated flasks.
  • MOI multiplicity of infection
  • A549 cells were infected with the HAdV-A12, -B3 or -C2 strain at a multiplicity of infection (MOI) of 0.03 or 3 in Dulbecco’s Modified Eagle’s medium (Gibco) supplemented with 2% fetal calf serum (Gibco) and 10 mM of L-glutamine.
  • MOI multiplicity of infection
  • cDNA was obtained by reverse transcription of 1 pg of RNA using iScript cDNA Synthesis Kit (Bio-rad) following manufacturer’ s instructions.
  • the cDNA was subj ected to qPCR using TakyonTM No Rox SYBR 2X MasterMix blue dTTP (Eurogentec) and CFX96TM lOOOTouch Real-Time PCR System (Biorad).
  • the primers used to titrate A3B were designed by Refsland and colleagues (Refsland et al., 2010).
  • A549 cells were infected with serial dilutions of HAdV stocks or supernatants containing virions in DMEM supplemented with 2% FCS. After twenty-four hours, cells were fixed with a mix of methanol/acetone 1 : 1 and incubated 5 min at -20°C. Cells were then washed once with PBS and permeabilized using the permeabilization buffer (Invitrogen) according manufacturer’s instructions. Cells were then incubated one hour at 4°C with anti -HAdV antibody (MAB 8051, Sigma- Aldrich) used at a dilution of 1 :200 in permeabilization buffer supplemented with 2% of goat serum (Gibco).
  • Cells were fixed and permeabilized using the eBiosciencesTM Foxp3/Transcri ption Factor Staining Buffer set (InvitrogenTM) according manufacturer’s instructions. Cells were then incubated 30 minutes at 4°C with anti-HAdV antibody (MAB 8051, Merck Millipore) used at a dilution of 1 :200 in permeabilization buffer supplemented with 2% of goat serum (Gibco). After 2 washes in permeabilization buffer supplemented with goat serum, cells were incubated 30 minutes with an anti-mouse antibody coupled with phycoerythrin (Miltenyi Biotec).
  • anti-HAdV antibody MAB 8051, Merck Millipore
  • HAdV-infected cells were washed two times with permeabilization buffer supplemented with 2% of goat serum and then resuspended in PBS. Percentage of HAdV-infected cells was quantified using BD FACSVerse Flow Cytometer and BD FACSuite vl.0.6 software (BD Biosciences).
  • Hsp90 was used as loading control and was detected with an anti-HSP90ABl antibody (Sigma-Aldrich) at a dilution of 1 : 1000 in TBS supplemented with 0.1% Tween 20 and 5% BSA.
  • An HRP-coupled anti -rabbit IgG secondary antibody (Dako) was used at a dilution of 1 :2000 in TBS with 0.1% Tween 20 and 5% BSA or 4% milk.
  • Membranes were incubated with the chemoluminescent SuperSignal TM West Femto Maximun Sensitivity Substrate (ThermoFisher Scientific) and chemoluminescence was read using an ImageQuant LAS4000 (GE Healthare Life Sciences). Densitometry analysis was done using Imaged software. Deamination assay
  • RNAse A (Thermofisher Scientific). Reaction mixture was treated with 50 mM NaOH and heated to 95°C for 10 min to cleaved DNA probes at the abasic site. Reaction mixture was then neutralized with 50 mM HC1 and mixed with 1.25x formamide buffer.
  • Substrates (43 bases-long) from products (30 bases-long) were separated on a 15% tris- borate-EDTA (TBE)-urea gel.
  • the Cy5-labeled substrates and deamination products were detected using ImageQuant LAS4000 mini (GE Healthcare Life Sciences). Densitometry analysis was done using ImageJ software.
  • A3B and viral replication centers subcellular localization by immunofluorescence microscopy
  • A549 cells were treated with EdU (Click-iTTM Plus EdU Cell Proliferation Kit for Imaging, Invitrogen) at a final concentration of 10 pM according the manufacturer’s instructions. After one hour of incubation, cells were fixed with a mix of methanol/acetone 1 : 1 and incubated 5 min at - 20°C. Cells were then washed once with PBS and permeabilized using the permeabilization buffer (Invitrogen) according manufacturer’s instructions.
  • EdU Click-iTTM Plus EdU Cell Proliferation Kit for Imaging, Invitrogen
  • NTC ratio is given as the log2 ratio of the observed occurrence of the NTC codon to its expected occurrence.
  • the NTC codon includes the ATC, CTC, GTC and TTC codons.
  • each coding sequence has been randomly shuffled a thousand times, retaining only the nucleotide composition.
  • the expected count of NTC codons is calculated as the average of the occurrences of this codon over the thousand iterations.
  • a “synthetic coding genome” was generated by concatenating the different coding sequences. The synthetic coding sequence is then randomly shuffled a thousand times and NTC ratio calculated as above. A NTC ratio less than zero indicates NTC under representation and a NTC ratio equal to zero means that no representation bias is observed.
  • A3B limits the propagation of adenoviruses by a deaminase -dependent mechanism
  • the human epithelial bronchial cells (HBEC3-KT, thereafter named HBEC-WT) were transduced by lentiviral vectors in order to induce a constitutive expression of A3B.
  • Three different cell lines were established: the HBEC-A3B cells (expressing an enzymatically active A3B protein), the HBEC-A3B-DD cells (producing a Deaminase Dead A3B mutant) and the HBEC-GFP cells as control.
  • the levels of A3B mRNA in the HBEC-A3B and HBEC-A3B-DD cells are increased by more than 100 folds compared to WT, whereas GFP expression does not impact A3B mRNA level (Figure 1A).
  • the HBEC-A3B and A3B-DD express high and comparable levels of A3B protein ( Figure
  • HBEC-WT, HBEC-A3B, HBEC-A3B-DD and HBEC-GFP were infected with the different adenoviral strains A12, B3 and C2 at a low MOI (0.03) and monitor viral replication in the 4 cell lines.
  • Figure 2A shows the viral DNA load detected in the cells by qPCR at different time-points post-infection and expressed relative to the viral load measured in the WT infected cells. The viral load is decreased in the HBEC-A3B cells but not in the GFP nor in the A3B-DD cells.
  • Figure 2B shows the amount of viral DNA in the supernatant measured by qPCR and expressed relative to the WT infected cells. This amount is decreased in the conditions where the HBEC-A3B cells were infected with the A12 strain. The decrease can also be observed for the B3 and C2 albeit with a much lower magnitude.
  • Figure 2C shows the percentage of infected cells measured by flow cytometry and relative to the WT infected cells.
  • A3B restricts the replication of these different adenoviral strains, the deaminase activity of the protein is required, and the magnitude of the effect is influenced by the strain of the virus, some being more sensitive to the A3B-mediated restriction than others.
  • A3B reduces viral load, progression to late phase, and production of infectious viral particles
  • Figure 3C shows that the A12- and B3-infected cells expressing the enzymatically active A3B protein produce a lower amount of infectious viral particles than their WT counterpart.
  • the lower production of infectious viral particles in the HBEC-A3B cells ( Figure 3C) is certainly explained by the lower viral DNA load ( Figure 3B)
  • A3B does not impact the entry of the virus, nor the expression of immediate early genes. Rather, A3B decreases viral DNA replication and delays the progression into the late phase resulting in a lower production of infectious viral particles.
  • APOBEC3B hyper-mutates the viral genome of the Al 2, B3 and C2 strains
  • Figure 4A illustrates the E4-specific 3DPCR amplicons obtained during HAdV- A12 infection of WT-, GFP-, A3B- and A3B-DD-expressing cells. Low denaturation temperature amplicons were observed (Figure 4A) in the 3DPCR reactions done on the DNA extracted from A3B-expressing cells but not from the other cell lines.
  • Figure 4B reports the 3DPCR results for the 3 viral genes (E1B, L3 and E4), the 3 viral strains (A12, B3 and C2) and the 4 cell lines (WT, GFP, A3B and A3B-DD).
  • Amplicons from A3B-expressing cells were recovered at a denaturation temperature of 86, 82.2 and 81.3°C for respectively the E1B, L3 and E4 3DPCR reactions. Two different and representative sequences were reported for each gene. Deamination events were observed in both the coding (C to T mutations) and template strand (C to T mutations in the template strand resulting in G to A mutations in the coding strand) viral sequences. As expected, when a hypermutated sequence is recovered, the mutations are almost exclusively either C to T (mutations of the coding strand) or G to A (C to T mutations of the template strand).
  • Figure 4D shows that the mutations recorded in the hyper-mutated clones are almost exclusively C to T or G to A (making more than 97% of the mutations).
  • Figure 4E shows an enrichment for a T in 5’ of the mutated C, both in the E1B, L3 and E4 hyper-mutated sequences. This context is typical for the A3 proteins (with the sole exception of A3G that favors deamination of a C following another C).
  • A3B knockout promotes replication of strain Al 2
  • FIG. 6B The A549 lung cancer cell line that constitutively expresses A3B was used (Figure 6B).
  • the A549 cells were transduced with lentiviral vectors expressing shRNAs against A3B (shA3B) or scramble control (scramble).
  • Figure 5A shows that A549-shA3B produces 26 times less mRNA that the WT or scramble control.
  • Figure 5B shows that the A549-shA3B barely express the A3B protein
  • Figure 5C shows that A549-shA3B does not display deaminase activity on the contrary to the WT or scramble controls.
  • FIG. 6A shows the viral DNA load detected in the cells by qPCR at different time-points post-infection and relative to the load measured in the WT infected cells.
  • the viral load in the A549-shA3B cells infected with the A12 strain is increased at 2- and 4-days post infection. On the contrary, no difference was observed in the cells infected with the B3 nor with the C2 strain.
  • Figure 6B shows the amount of viral DNA in the supernatant measured by qPCR and expressed relative to the amount present in the supernatant of WT infected cells.
  • the viral load in the supernatant of the A549-shA3B cells infected with the A12 strain is increased at 4- and 7-days post infection.
  • Figure 6C shows the percentage of infected cells measured by flow cytometry and relative to the WT conditions. The percentage of A12-infected cells is increased in the A549-shA3B cells at 4- and 7-days post infection whereas no difference was observed for the B3 and C2 strains.
  • Figure 7A illustrates the L3-specific 3DPCR amplicons obtained during HAdV-A12 infection of WT, scramble, and shA3B cells. Low denaturation temperature amplicons were observed (Figure 7A) in the 3DPCR reactions done on the DNA extracted from WT and scramble cells but not from shA3B cells, indicating that A3B is necessary for the generation of hyper-mutated viruses.
  • Figure 7B reports the 3DPCR results for the 3 viral genes (E1B, L3 and E4), the 3 viral strains (A12, B3 and C2) and the 3 cell lines (WT, scramble and shA3B).
  • Albeit A3B hypermutates the genomes of the three strains, it impacts more strongly the replication of A12 strain than the B3 or the C2. To understand these differences, A3B was studied at the transcriptional and protein levels and its enzymatic activity and subcellular localization was measured in A549 cells infected with each of the three strains. A549 cells were infected at a high MOI (MOI 3).
  • Figure 8A shows that infection of A549 cells with the A12 strain does not modify the level of the A3B protein, whereas a significant decrease of the protein amount can be detected in the cells infected with the B3 and the C2 strains after 1- and 2-days post infection (lanes 3, 4, 7 and 8).
  • Figure 8B shows that the levels of A3B mRNA transcripts were not impacted by the B3 nor the C2 infection, and a slight increase can be observed in the A12-infected cells at 2-days post infection as compared with mock-infected cells. Therefore, the decrease of the A3B protein observed in the B3- and to a lesser extent in the C2-infected cells is not due to transcriptional changes.
  • Figure 8C shows that the deaminase activity of the cell lysates is significantly decreased for the 3 strains, the magnitude of the decrease being stronger in the B3- and C2-infected cells.
  • the loss of deaminase activity of the cell lysates isolated from the B3- and C2-infected cells was expected as the amount of the A3B protein has been significantly reduced.
  • the infection with the A12 did not significantly modify the total amount of the A3B protein, the deaminase activity in the A12 infected cells is being reduced (Figure 8C).
  • the three adenoviral strains antagonize the A3B protein by reducing its quantity and/or its enzymatic activity depending on the strain.
  • A3B protein is distributed homogeneously in the nucleus of mock- infected cells.
  • the A3B labelling is weak in C2- and ever weaker in B3-infected cells.
  • the A3B protein forms dense clusters in the nucleus of A12-infected cells. Strikingly, these clusters are located at the center of the viral replication centers as labelled by the incorporation of EdU. Because adenoviruses replicate by strand displacement, the displaced strand represents the prototypical substrate for the editing by A3B.
  • Adenoviruses of a given species share a similar A3 footprint
  • the A3s will turn 5’TC motifs into 5’TU dinucleotides in the genome of exposed viruses.
  • the mutation can be synonymous or nonsynonymous.
  • deamination of the C will turn the NTC codon into an NTT codon.
  • This mutation will always be synonymous.
  • A3-related deamination intervenes on a C located at the first position of a codon, the NNTCNN motif will be converted into an NNTUNN motif and will produce a nonsynonymous mutation.
  • the A3 -driven natural selection should deplete more intensively NTC codons than TCN or NNTCNN motifs (as in those cases the C to U mutation will impact the encoded amino acid).
  • the APOBEC3 footprint was defined as an under-representation of NTC codons because A3s favor 5’-TC motifs and because a C to U mutation in the third position of a codon is likely to be retained.
  • Figure 9 shows that adenoviruses of the species A display an occurrence of NTC codons lower than expected.
  • the level of NTC under-representation is similar between the four strains of adenoviruses A (namely A12, A18, A31 and A61) and is lower than any other species. It can be speculated that, like the A12, the other A strains are less able to antagonize A3B and therefore evolved to reduce the number of A3 -favored motifs.
  • the A3 footprint is relatively homogenous.
  • the B, D, E and G species show no NTC depletion on average for the whole viral genome, whereas the C and the F species display a moderate under-representation of NTC codon.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un adénovirus ou un fragment de celui-ci destiné à être utilisé en tant qu'adjuvant pour le traitement du cancer chez un sujet en ayant besoin. Le principe actif est un agent anticancéreux, de préférence un virus oncolytique. La présente invention concerne en outre un procédé d'inhibition de l'APOBEC3B.
PCT/EP2023/073420 2022-08-26 2023-08-25 Adjuvants à base d'adénovirus pour le traitement du cancer Ceased WO2024042231A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22192313.9 2022-08-26
EP22192313 2022-08-26

Publications (1)

Publication Number Publication Date
WO2024042231A1 true WO2024042231A1 (fr) 2024-02-29

Family

ID=83508353

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/073420 Ceased WO2024042231A1 (fr) 2022-08-26 2023-08-25 Adjuvants à base d'adénovirus pour le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2024042231A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160120922A1 (en) * 2013-06-14 2016-05-05 Psioxus Therapeutics Limited A Dosing Regime and Formulations for Type B Adenovirus
US20190358277A1 (en) * 2016-12-09 2019-11-28 Genemedicine Co., Ltd. Anticancer composition comprising recombinant adenovirus expressing degradation factor for extracellular matrix
US20200323932A1 (en) * 2017-04-21 2020-10-15 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160120922A1 (en) * 2013-06-14 2016-05-05 Psioxus Therapeutics Limited A Dosing Regime and Formulations for Type B Adenovirus
US20190358277A1 (en) * 2016-12-09 2019-11-28 Genemedicine Co., Ltd. Anticancer composition comprising recombinant adenovirus expressing degradation factor for extracellular matrix
US20200323932A1 (en) * 2017-04-21 2020-10-15 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JIAN GAO ET AL: "State-of-the-art human adenovirus vectorology for therapeutic approaches", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 593, no. 24, 9 December 2019 (2019-12-09), pages 3609 - 3622, XP071256803, ISSN: 0014-5793, DOI: 10.1002/1873-3468.13691 *
LEJEUNE NOÉMIE ET AL: "Infection of Bronchial Epithelial Cells by the Human Adenoviruses A12, B3, and C2 Differently Regulates the Innate Antiviral Effector APOBEC3B", vol. 95, no. 13, 10 June 2021 (2021-06-10), US, XP093021378, ISSN: 0022-538X, Retrieved from the Internet <URL:https://journals.asm.org/doi/pdf/10.1128/JVI.02413-20> DOI: 10.1128/JVI.02413-20 *
LEJEUNE NOÉMIE ET AL: "The APOBEC3B cytidine deaminase is an adenovirus restriction factor", PLOS PATHOGENS, vol. 19, no. 2, 6 February 2023 (2023-02-06), pages e1011156, XP093048847, DOI: 10.1371/journal.ppat.1011156 *
POULAIN FLORIAN ET AL: "Footprint of the host restriction factors APOBEC3 on the genome of human viruses", PLOS PATHOGENS, vol. 16, no. 8, 14 August 2020 (2020-08-14), pages e1008718, XP093021336, DOI: 10.1371/journal.ppat.1008718 *

Similar Documents

Publication Publication Date Title
US20230390379A1 (en) Respiratory syncytial virus vaccine
US20230116376A1 (en) Human cytomegalovirus rna vaccines
US20250228932A1 (en) Human cytomegalovirus vaccine
US11752206B2 (en) Herpes simplex virus vaccine
JP2022037134A (ja) 単純ヘルペスウイルスワクチン
US20200054737A1 (en) Herpes simplex virus vaccine
US10688164B2 (en) CMV vectors comprising microRNA recognition elements
EP3364949A1 (fr) Vaccins anticancéreux
KR20180094859A (ko) 수두 대상포진 바이러스 (vzv)를 위한 핵산 백신
CN105209617B (zh) 微囊泡及其制造方法
US20250188493A1 (en) Recombinant viral vector and uses thereof
WO2024042231A1 (fr) Adjuvants à base d&#39;adénovirus pour le traitement du cancer
US20220280601A1 (en) METHOD FOR TREATMENT OF HEPATIC CANCER USING REIC/Dkk-3 GENE IN COMBINATION WITH ANTI-TUMOR AGENT
US20210268049A1 (en) Methods and compositions for treatment of solid cancers and microbial infection
US20110105589A1 (en) Apoptosis inducer
JP6640717B2 (ja) レトロウイルス複製ベクターと関連する免疫抑制成分
JP2016023182A (ja) がんを処置するための医薬
CN106310214A (zh) 流感病毒蛋白与宿主蛋白cpsf30的相互作用在抑制癌细胞增殖中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23761904

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23761904

Country of ref document: EP

Kind code of ref document: A1